Zobrazeno 1 - 10
of 190
pro vyhledávání: '"Christopher J, Patterson"'
Autor:
Xia Liu, Jiaji G. Chen, Manit Munshi, Zachary R. Hunter, Lian Xu, Amanda Kofides, Nickolas Tsakmaklis, Maria G. Demos, Maria Luisa Guerrera, Gloria G. Chan, Cristina Jimenez, Christopher J. Patterson, Kirsten Meid, Andrew Keezer, Jorge J. Castillo, Steven P. Treon, Guang Yang
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 141-153 (2020)
Abstract: Hematopoietic cell kinase (HCK) is an SRC family member that is aberrantly upregulated in B-cell neoplasms dependent on MYD88-activating mutations and supports their growth and survival. We showed herein that activation of Toll-like recepto
Externí odkaz:
https://doaj.org/article/f0c549eb05534163bf4e7c11455f1321
Autor:
Amanda Kofides, Zachary R. Hunter, Lian Xu, Nicholas Tsakmaklis, Maria G. Demos, Manit Munshi, Xia Liu, Maria Luisa Guerrera, Carly R. Leventoff, Timothy P. White, Catherine A. Flynn, Kirsten Meid, Christopher J. Patterson, Guang Yang, Andrew R. Branagan, Shayna Sarosiek, Jorge J. Castillo, Steven P. Treon, Joshua N. Gustine
Publikováno v:
HemaSphere, Vol 5, Iss 8, p e624 (2021)
Externí odkaz:
https://doaj.org/article/24e61dfdebac48c1b54aaa8f7c982571
Autor:
Joshua N. Gustine, Shayna Sarosiek, Catherine A. Flynn, Kirsten Meid, Carly Leventoff, Timothy White, Maria Luisa Guerrera, Lian Xu, Amanda Kofides, Nicholas Tsakmaklis, Manit Munshi, Maria Demos, Christopher J. Patterson, Xia Liu, Guang Yang, Zachary R. Hunter, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo
Publikováno v:
Haematologica, Vol 107, Iss 5 (2021)
Ibrutinib is highly active and produces long-term responses in patients with Waldenström macroglobulinemia (WM), but acquired resistance can occur with prolonged treatment. We therefore evaluated the natural history and treatment outcomes in 51 WM p
Externí odkaz:
https://doaj.org/article/56e793968d144ede8278e7e6afb13222
Autor:
Joshua N. Gustine, Lian Xu, Nicholas Tsakmaklis, Maria G. Demos, Amanda Kofides, Jiaji G. Chen, Xia Liu, Manit Munshi, Maria Luisa Guerrera, Gloria G. Chan, Christopher J. Patterson, Andrew Keezer, Kirsten Meid, Toni Dubeau, Guang Yang, Zachary R. Hunter, Steven P. Treon, Jorge J. Castillo
Publikováno v:
Blood Advances, Vol 3, Iss 19, Pp 2800-2803 (2019)
Externí odkaz:
https://doaj.org/article/c0cacde5eb6e4167bd409e330e343bec
Autor:
Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Catherine A. Flynn, Maria G. Demos, Maria L. Guerrera, Cristina Jimenez, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Christopher J. Patterson, Lian Xu, Guang Yang, Zachary R. Hunter, Steven P. Treon
Publikováno v:
HemaSphere, Vol 4, Iss 3, p e363 (2020)
Abstract. Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter, phase II trial in previously treated WM patients. We sought to evaluate whether ther
Externí odkaz:
https://doaj.org/article/141760b83a474b2d84cd37e9f0f50644
Autor:
Eric Kai Chung Wong, Justin Yusen Lee, Darryl P. Leong, Lawrence Mbuagbaw, Haroon Yousuf, Sabina Keen, Sharon E. Straus, Christopher J. Patterson, Catherine Demers
Publikováno v:
Pilot and Feasibility Studies, Vol 4, Iss 1, Pp 1-7 (2018)
Abstract Background Heart failure (HF) is a major cardiovascular disease with increasing prevalence. Thiamine deficiency occurs in 33% of patients with HF. However, the effectiveness of thiamine supplementation in HF is not known. Methods In a placeb
Externí odkaz:
https://doaj.org/article/562f977ead334118a8355167634095e7
Publikováno v:
Seminars in Hematology.
Autor:
Jorge J. Castillo, Shayna R. Sarosiek, Joshua N. Gustine, Catherine A. Flynn, Carly R. Leventoff, Timothy P. White, Kirsten Meid, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Zachary R. Hunter, Christopher J. Patterson, Andrew R. Branagan, Steven P. Treon
Publikováno v:
Blood Advances. 6:1015-1024
Bruton tyrosine kinase (BTK) inhibitors are the only FDA-approved treatments for Waldenström macroglobulinemia (WM). Factors prognostic of survival and predictive of response to BTK inhibitors remained to be clarified. We evaluated 319 patients with
Autor:
Christopher J. Patterson, Lian Xu, Tanya Siddiqi, Maria Luisa Guerrera, Shayna Sarosiek, Zachary R. Hunter, Andrew R. Branagan, Xia Liu, Carly Leventoff, Catherine A Flynn, Ranjana H. Advani, Kirsten Meid, Nicholas Tsakmaklis, Maria Demos, Matthew S. Davids, Guang Yang, Amanda Kofides, Timothy P White, Manit Munshi, Steven P. Treon, Jorge J. Castillo, Richard R. Furman, John N. Allan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(1)
PURPOSE BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenström macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in vitro apoptosis of WM cells. The activity of venetocla
Autor:
Amanda Kofides, Kirsten Meid, Sara J. Buhrlage, Jinhua Wang, Manit Munshi, Jorge J. Castillo, Jiaji G. Chen, Kenneth C. Anderson, Michael D. Cameron, Guang Yang, Maria Luisa Guerrera, Xia Liu, Lian Xu, Nicholas Tsakmaklis, Nikhil C. Munshi, Jianwei Che, Li Tan, Maria Demos, Nathanael S. Gray, Christopher J. Patterson, Steven P. Treon, Zachary R. Hunter
Publikováno v:
Blood
Activating mutations in MYD88 promote malignant cell growth and survival through hematopoietic cell kinase (HCK)–mediated activation of Bruton tyrosine kinase (BTK). Ibrutinib binds to BTKCys481 and is active in B-cell malignancies driven by mutate